(HealthDay News) — Among men with non-metastatic prostate cancer, treatment with androgen deprivation therapy is associated with an increased risk of developing acute kidney injury, according to a study published in the July 17 issue of the Journal of the American Medical Association.
Francesco Lapi, Pharm.D., Ph.D., from Jewish General Hospital in Montreal, and colleagues assessed the incidence of acute kidney injury in 10,250 men newly diagnosed with non-metastatic prostate cancer treated with androgen deprivation therapy.
During a mean follow-up of 4.1 years, the researchers identified 232 incident cases of acute kidney injury. Compared with up to 20 controls per case not treated with androgen deprivation therapy matched for age, calendar year of prostate cancer diagnosis, and duration of follow-up, patients receiving androgen deprivation therapy had a significantly higher risk of developing acute kidney injury (odds ratio, 2.48, with a rate difference of 4.43 per 1,000 persons per year). The association was largely due to a combined androgen blockade with gonadotropin-releasing hormone agonists plus oral antiandrogens, estrogens, other combination therapies, and gonadotropin-releasing hormone agonists.
“In a cohort of patients with newly diagnosed non-metastatic prostate cancer, the use of androgen deprivation therapy was significantly associated with an increased risk of acute kidney injury,” Lapi and colleagues conclude.
Two authors disclosed financial ties to pharmaceutical companies.